A Phase 3 trial of the oral drug DCC-2618 vs. placebo is now open and recruiting patients.  Participants must have received imatinib, sunitinib, and regorafenib in order to qualify for participation. The study is being done to learn more about the safety of DCC-2618 and how well it works against cancer in patients who have received prior anticancer treatments.  The study name is “Invictus” and here is the link to the website:  http://www.invictusclinicalstudy.com

Patients can go onto the website to do their own pre-screening to see if they are eligible for the study and then navigate the next steps to enrollment, etc.  The trial can be viewed at: https://clinicaltrials.gov/ct2/show/NCT03353753